CRISPR Therapeutics AG
CRSP News Today: Stay Updated with the Latest CRISPR Therapeutics AG News in Real Time
Find CRSP news now at Meyka AI. Stay informed with the latest CRISPR Therapeutics AG stocks updates, including price news, market analysis, and expert insights.
VTI Stock Today: March 15 – Diversification vs S&P 500 Amid AI Boom
VTI stock vs S&P 500 in an AI-led market: diversification, performance context, technical setup, and $1M compounding scenarios for U.S. investors weighing VTI vs VOO.
MMTX.SW MindMaze (SIX) up 8.98% pre-market 14 Mar 2026: watch volume
MMTX.SW stock jumps 8.98% pre-market on 14 Mar 2026 with volume surge; short-term technicals and Meyka AI forecast reviewed
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026
Oppenheimer maintains Outperform and raises NKTR analyst rating PT to $140 on March 13, 2026
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026
Jefferies maintains Hold on Mineralys Therapeutics; MLYS analyst rating updated March 2026 with PT cut to $30
Cantor Fitzgerald Maintains Overweight on CMPX (Compass Therapeutics, Inc.), Mar 2026
Cantor Fitzgerald maintains CMPX analyst rating Overweight on Mar 12, 2026 ahead of PFS/OS readout
Outperform Maintained on Tenaya Therapeutics (TNYA) by Leerink and William Blair March 2026
TNYA analyst rating: Leerink and William Blair maintained Outperform on Tenaya Therapeutics in March 2026
Pre-market: Relief Therapeutics RLF.SW CHF2.89 on 13 Mar 2026: bounce watch
Pre-market snapshot of RLF.SW stock at CHF2.89; oversold bounce setup, fundamentals, Meyka AI forecast and risks
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026
Jefferies maintains Buy on VKTX analyst rating in March 2026; implications, market reaction, and Meyka AI grade for VKTX
PRFN.SW Kinarus Therapeutics (SIX) -8.12% 12 Mar 2026: volume spike adds risk
PRFN.SW stock fell to CHF0.0362 on 12 Mar 2026; heavy volume and Meyka AI forecast point to higher short-term volatility